The Complex Landscape of U.S. Drug Pricing and 340B Program Challenges

This chapter explores the intricate dynamics of drug pricing in the United States, focusing on the clash among pharmaceutical companies, pharmacy benefit managers, and regulatory bodies. It also discusses recent pressures for price reductions and introduces new pricing models, shedding light on the implications for healthcare providers and patients.